Episode 4 of Quantum Computing Business with Fexingo dives into the real-world business case for quantum in drug discovery. Lucas and Luna examine 2025 data from the first pharma companies posting cost-per-molecule reductions using noisy intermediate-scale quantum (NISQ) hardware. They break down a concrete example: how one mid-size biotech simulated a 20-atom molecule classically for $80,000 per simulation, then ran the same problem on a hybrid quantum-classical workflow for under $12,000 — a sixfold savings even before error mitigation. The hosts explore why quantum is winning on cost for specific molecular simulations, where the break-even point sits today, and what the next three years look like as hardware scales. No hype, no theory — just the numbers that matter for CFOs and R&D heads.

#QuantumComputing #DrugDiscovery #NISQ #CostEfficiency #QuantumBusiness #Pharma #Simulation #HybridQuantum #MolecularModeling #ErrorMitigation #BusinessPodcast #FexingoBusiness #LucasAndLuna #EnterpriseTech #R&D #Biotech #ROIC #QuantumAdvantage

Keep every episode free: buymeacoffee.com/fexingo